Pharmaceuticals Company Investment Opportunity in Hyderabad, India
Pharmaceuticals start-up developing enhanced versions of naproxen, irinotecan and aspirin seeks funds for FDA approval.
Premium Plan
| Established | 5-10 year(s) |
| Employees | 2 - 5 |
| Legal Entity | Private Limited Company |
| Reported Sales | Nil |
| Run Rate Sales | Nil |
| EBITDA Margin | Nil |
| Industries | Pharmaceuticals |
| Locations | Hyderabad |
| Local Time | 10:58 AM Asia / Kolkata |
| Listed By | Business Owner / Director |
| Status | Active |
Partial Stake Sale
USD
590 thousand
for
20.0%
stake
(Native Currency: INR 50,000,000)
Reason: Our immediate objective is to develop Enhanced Naproxen through the 505 (b) (2) NDA route in the USA...
View More
Includes physical assets worth
USD
237
Interested to connect with advisors
Name, Phone, Email
Available after connect
Business Name
Available after connect
User Verification
Documents
US Patent Covering Enhanced Naproxen
(3.1 MB)
Pitch Deck
(1.0 MB)
Certificate of Incorporation (India)
(523.7 KB)
DPII-Recognized Startup
(327.6 KB)
ROC-Verification.pdf
(73.8 KB)
Business Overview
- We incorporated our startup both in Hyderabad, India five years back and in Foothill Ranch, California, USA one year ago.
- Our co-founders are a team of 5 experienced PhDs and a medical doctor with clinical research experience in 3 multi-national pharma companies. We also have a woman co-founder (an Indian national) with an MMS degree. We have also hired an experienced auditor (in India) /CPA (in the USA) to help us in regulatory filings with respective government authorities. We also have an experienced business advisor (an Indian national).
- Our co-founders have contributed >USD 108,000 so far.
- Currently developing 3 new chemical entities (NCEs): Enhanced Naproxen (E-Naproxen), Enhanced irinotecan (E-Irinotecan), and Enhanced Aspirin (E-Aspirin)
- Our initial focus is on the US market and we will bring our products to India and other major markets once we gain respectable sales figures in the US market.
- Planning to develop these NCEs in the USA through the most economical (<USD 10 million) and shortest (<1.5–2.5 years) USFDA’s 505 (b) (2) regulatory route, which also grants 3-5 years exclusivity along with approval.
- Currently, our NCEs are in the pre-clinical stage and will get all the regulatory approvals as per the requirement.
- After securing the required funding (or equivalent amount in INR), we will take up the development of our first product.
- Our startup was among the top 60 startups selected for acceleration under South Korea’s latest K-Startup Grand Challenge Program. Our CSO attended this acceleration program in Korea.
- We have already obtained three patents (US, Canadian and Indian patents) on Enhanced Naproxen and Enhanced Aspirin and we will file provisional patent applications on Enhanced Irinotecan as soon as we secure the required seed funding.
- Our co-founders are a team of 5 experienced PhDs and a medical doctor with clinical research experience in 3 multi-national pharma companies. We also have a woman co-founder (an Indian national) with an MMS degree. We have also hired an experienced auditor (in India) /CPA (in the USA) to help us in regulatory filings with respective government authorities. We also have an experienced business advisor (an Indian national).
- Our co-founders have contributed >USD 108,000 so far.
- Currently developing 3 new chemical entities (NCEs): Enhanced Naproxen (E-Naproxen), Enhanced irinotecan (E-Irinotecan), and Enhanced Aspirin (E-Aspirin)
- Our initial focus is on the US market and we will bring our products to India and other major markets once we gain respectable sales figures in the US market.
- Planning to develop these NCEs in the USA through the most economical (<USD 10 million) and shortest (<1.5–2.5 years) USFDA’s 505 (b) (2) regulatory route, which also grants 3-5 years exclusivity along with approval.
- Currently, our NCEs are in the pre-clinical stage and will get all the regulatory approvals as per the requirement.
- After securing the required funding (or equivalent amount in INR), we will take up the development of our first product.
- Our startup was among the top 60 startups selected for acceleration under South Korea’s latest K-Startup Grand Challenge Program. Our CSO attended this acceleration program in Korea.
- We have already obtained three patents (US, Canadian and Indian patents) on Enhanced Naproxen and Enhanced Aspirin and we will file provisional patent applications on Enhanced Irinotecan as soon as we secure the required seed funding.
Products & Services Overview
We are developing the following three new chemical entities (NCEs):1) Enhanced Naproxen (E-Naproxen)
2) Enhanced irinotecan (E-Irinotecan)
3) Enhanced Aspirin (E-Aspirin)
Assets Overview
Non-Current Assets:Tangible (Office Furniture): 20,114 INR (~243 USD as of Dec 17, 2022)
Intangible Assets (Intellectual Property and Patents):
- Three Issued Patents on Enhanced Naproxen and Enhanced Aspirin: US 9,844,599 (19-12-2017); CA 2897571C (18-12-2018); IN345054 (25-08-2020);
- We will file patent application on Enhanced Irinotecan after securing the seed funding.
Current Tangible Assets (Cash and cash equivalent):
Augment Therapeutics Pvt Ltd (India): 3,19,113 INR (~3,857 USD as of Dec 17, 2022);
Augment Therapeutics, Inc. (USA): 14,116 USD (~11,67,817 INR as of Dec 17, 2022).
Facilities Overview
We intend to incubate at UoH-BioNEST incubator at University of Hyderabad, Telangana State, India, as soon as we get the required seed funding.
Capitalization Overview
Co-founders/shareholders of the Indian company Augment Therapeutics Private Limited and their contributions:1st shareholder (Indian Citizen woman) - 49% equity with INR 12,25,000 of share capital, 2nd shareholder (US Citizen & OCI) - 49% equity with INR 12,25,000 share capital and an additional contribution of INR 17,00,000, 3rd shareholder (Indian citizen) with 1% equity and INR 25,000 INR of share capital, and 4th shareholder with 1% equity and INR 25,000 INR of share capital.
Total contributions as share capital: INR 12,25,000 + INR 12,25,000 + INR 25,000 + INR 25,000 = INR 25,00,000.
Additional Contribution from a co-founder/director 17,00,000 INR.
Total contributions from co-founders (share capital + additional contr. ): INR 25,00,000 + INR 17,00,000 = INR 42,00,000.
The equivalent amount in USD (42,00,000/82.73) is INR = 50,768 USD.
Co-founders/Shareholders (all US Citizens) of the USA entity and their contributions:
Indian entity - 49% with USD 4,900 of share capital; 2nd shareholder - 10%, USD 1,000 of share capital and USD 11,000 of additional contribution; 3rd shareholder - 15%, USD 1,500 of share capital and USD 15,500 of additional contribution; 4th shareholder - 10%, USD 1,000 of share capital and USD 11,000 of additional contribution; 5th shareholder - 10%, USD 1,000 of share capital and USD 11,000 of additional contribution; 6% of unassigned shares.
Total contributions (share capital + additional contr. ): USD 9,400 + USD 48,500 = USD 57,900.
Total contributions from co-founders/shareholders of both Indian and US entities: USD 50, 768 + USD 57,900 = USD 108,668 (INR ~8,990,104 INR)
Recent Activity
-
Earlier than 15 daysPartner, Construction & Real Estate, Hyderabad, Individual Investor / Buyer connected with the Business
-
Earlier than 15 daysCEO, Delhi, M&A Advisor connected with the Business
-
Earlier than 15 daysSenior Investor, Investment Management, Massachusetts, Individual Investor / Buyer connected with the Business
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
Contact Business
57 Investors already contacted this Business.
Register below to connect now!
- Social
- Register
- Login
Who uses SMERGERS?
... and 116,500+ other businesses of all sizes.
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct.
You might also be interested in these businesses